Key Takeaways
- Pharmaceutical giant Eli Lilly has agreed to purchase private biotech firm Merida Biosciences in an all-cash deal valued at up to $2.88 billion.
- The acquisition provides Lilly access to MER511, an experimental therapy for Graves’ disease and thyroid eye disease currently in early-stage trials.
- Merida’s development portfolio features MER769, which targets food allergies, asthma, and additional allergic disorders.
- This transaction marks Lilly’s second major immunology acquisition in 2026, following the $2.4 billion Orna Therapeutics deal.
- Shares of LLY declined 0.3% during premarket hours Monday after the acquisition was disclosed.
Pharmaceutical powerhouse Eli Lilly revealed plans Monday to acquire biotech company Merida Biosciences in a cash transaction worth as much as $2.88 billion. The agreement combines an initial upfront payment with performance-based milestone considerations, and the companies anticipate finalizing the deal during the fourth quarter of 2026.
LLY shares edged down 0.3% in early premarket activity following the announcement.
The privately held Merida specializes in developing biological therapies designed to selectively neutralize disease-causing antibodies associated with autoimmune disorders and allergic reactions. The company’s primary asset, MER511, is currently undergoing initial clinical testing for both Graves’ disease and thyroid eye disease.
Graves’ disease triggers thyroid overactivity, resulting in excessive hormone production. Meanwhile, thyroid eye disease may cause swelling, protruding eyes, impaired vision including double vision, and potential sight loss.
Lilly reported that preliminary clinical results demonstrated MER511 significantly reduced thyroid-stimulating antibodies responsible for these conditions, while exhibiting an encouraging preliminary safety record.
Existing therapeutic options for Graves’ disease encompass antithyroid drugs, radioactive iodine therapy, and surgical intervention. For thyroid eye disease, the FDA has authorized two medications: Tepezza from Amgen and Lumvoa from Viridian Therapeutics.
Strengthening Immunology Capabilities
This Merida acquisition represents Lilly’s continued strategy to bolster its immunology development programs. Earlier this year in February 2026, the pharmaceutical company announced its intent to purchase Orna Therapeutics, which focuses on B-cell-targeted autoimmune treatments, for $2.4 billion in cash.
Beyond its flagship program, Merida maintains a broader therapeutic pipeline. The experimental candidate MER769 addresses food allergies, asthma, and related allergic conditions, while additional early-stage initiatives focus on renal and immune-mediated diseases.
“Merida’s lead program is designed to do exactly that,” said Francisco Ramirez-Valle, Lilly’s senior vice president of immunology research and early clinical development, referring to therapies that change the course of disease rather than just its effects.
Accelerated Acquisition Strategy
Lilly’s merger and acquisition tempo throughout 2026 has exceeded previous years. During the second quarter, the company finalized purchases of both Kelonia Therapeutics and Ajax Therapeutics, each strengthening its hematological oncology portfolio.
In the final days of June, Lilly concluded its largest transaction of 2026, purchasing Centessa Pharmaceuticals for $7.8 billion, securing therapies addressing neurological conditions and sleep-wake disturbances, including narcolepsy treatments.
According to PitchBook analytics, biopharmaceutical mergers and acquisitions activity through early June 2026 totaled $106 billion spanning 201 separate deals. Lilly, commanding the highest market capitalization among pharmaceutical companies, has emerged as one of the sector’s most aggressive acquirers.
The corporation has primarily financed its acquisition campaign through substantial revenues generated by its GLP-1 weight management drug portfolio, while strategically diversifying growth opportunities beyond its core obesity and diabetes franchises.
Subject to standard regulatory approvals and closing requirements, the Merida acquisition is projected to conclude in the fourth quarter of 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
